JOIN THE MOVEMENT.
Over 1.4 million platelet units are treated with the INTERCEPT® Blood System each year.1
Find out why hospitals choose INTERCEPT® treated platelets
I saw the devastation that bacterial contamination could cause. It was something that I wanted to make sure would never happen again. When I learned that INTERCEPT® Platelets were available, it was a no-brainer to me to say, okay, we need to adopt this technology.
Mary Berg, MD
Medical Director, Transfusion Medicine Service
University of Colorado
Evaluating Usable Shelf-Life of Pathogen Reduced and LVDS Tested Platelet Components
Learn how INTERCEPT Blood System improves platelet availability in this webinar.
INTERCEPT Goes Beyond
*Broad spectrum transfusion transmitted infection risk reduction
The INTERCEPT® Blood System protects patients* through proactive, broad spectrum transfusion-transmitted infection risk reduction by inactivating bacteria, viruses, protozoans and leukocytes.2
*There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process.
The INTERCEPT® Blood System improves platelet availability with a day 1 release, which means the potential for earlier receipt, providing patients younger, fresher platelets.3 4
The INTERCEPT® Blood System delivers economic value and operational efficiencies by providing one transfusion-transmitted inventory for all patients and providing waste and cost reduction associated with testing and TTI risks.5 6
- Estimate for platelet units treated with the INTERCEPT Blood System is based on the number of kits sold per year. Total apheresis collections in 2021 was ~2.4M (Free RJ et al. Transfusion. 2023;1–11).
- INTERCEPT Blood System for Platelets Package Insert, Cerus Corporation; September 6, 2022.
- Collier, T. and Chrebtow , V. “Impact of Pathogen Reduction (PR) vs. LVDS Testing on Platelet Availability: A Study Based on Real-World Experience”. Cerus Corporation. AABB 2022. Poster P-IV-8.
- Prichard, A.B., et al. “Comparing Usable Shelf-Life of Pathogen Reduced Platelets vs. LVDS Screened Platelets.” OneBlood. AABB 2022. Poster P-IV-2.
- Harm SK, et al. Transfusion. 2018 Apr; 58(4):938-942.
- Ruby KN, et al. Transfusion. 2018 Jul; 58(7):1665-1669.